Nourish Ingredients

Nourish Ingredients' fate is tethered to a plant-based-meat category that is contracting, and "designer fat that makes alt-meat taste better" only matters if alt-meat itself sells — a flavor upgrade to a shrinking market is a shrinking opportunity, and the biggest buyers of B2B fat ingredients are exactly the plant-based-meat brands under the most commercial pressure. The company's manufacturing scale-up depends heavily on a single partner, CABIO Biotech in China, which concentrates supply-chain, geopolitical, and IP risk in one relationship at a time when Western food companies are increasingly wary of China-dependent supply chains. FEMA GRAS covers flavor use, but broad food-ingredient adoption still requires manufacturers to reformulate around a novel fermented lipid, a slow, reference-customer-gated process. Precision-fermented fats also face a cost reality check: even at low inclusion rates, the fermented ingredient must be cheap enough that adding it does not price the finished plant product out of competition with both conventional meat and cheaper all-plant alternatives. At roughly $40M raised, Nourish is thinly capitalized for a company building global manufacturing and two product lines (Tastilux and Creamilux) across meat and dairy simultaneously — and the last major disclosed raise dates to 2022. Commercial-scale production is a real achievement, but production capacity is only valuable if the demand it was built for materializes, and the alt-protein demand curve has bent the wrong way.